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Results

Background

Among the 26,000 genes detected using our computational pipeline, we discovered eleven candidate RNA
binding motifs from nine RBPs in or near correlated
events of transcriptional splicing (Fig. 3A).

Skeletal Stem Cells (SSCs) are the
progenitors of the skeletal system,
giving rise to bone, cartilage, and
stroma.1,2 These populations are defined by their functional output
both in-vitro and in-vivo, their ability
to self-proliferate, as well as their
molecular profile (Fig. 1).
Insights into aging and cancer of the
skeletal system have revealed fundamental changes to the transcriptomic landscape of SSCs
throughout life that govern their
ability to function as healthy stem
cells.3 Thus, we explore the significance of alternative splicing (AS) in
the skeletal system.

Discussion

A)

Our gene expression analysis and
rMATS modeling demonstrate the
prevalence of AS in hSSCs and osteosarcoma. The importance of AS in
hSSC maintenance and differentiation is demonstrated by a lack of
characteristic lineage differentiation of SSCs and by decrease in cell
number and viability.

The RBPs CPEB2, KHDRBS3, and PCBP3 demonstrated increased expression during the osteogenic differentiation time course (Fig 3B). Knockdown of KHDRBS3 and
CPEB2 by small interfering RNA during osteogenesis inhibited formation of bone in-vitro (data not shown).

In humans, >90% of protein-coding genes undergo post-translational AS.4 Through rearrangement of functional domains prior to translation, AS allows a single gene to encode a variety of proteins that may function in varying degrees of similarity or differ entirely in their activity. Recent advances in our understanding of human SSCs (hSSCs) and the skeletal niche have demonstrated the
need to examine AS as it relates to skeletal development, aging, loss of skeletal regenerative
capacity and skewing of hSSCs towards non-skeletogenic lineage fates. Moreover, mounting evidence that the progression of osteosarcoma corresponds with aberrations in the AS machinery,
producing cellular phenotypes that result in malignant tumors of the bone.

Inhibition of SF3B6 and SF3B1 by small molecule inhibitors prevents the formation of bone in-vitro and reduc3: Heatmaps of candidate RBPs from rMATS software. A) Log-transformed p
es cell viability by up to roughly 30% (Fig. 5A). Prolifera- Figure
values of candidate RBP motifs (y-axis) from RBNS and RNAcomplete motif datasets.
tion and differentiation to cartilage is also inhibited in-vi- Sequence logos are shown on the right of the heatmap. Statistically significant enrichment are indicated in positively (red) or negatively (blue) correlated foreground
tro with treatment of SF3B6 and SF3B1 inhibitors for both event sets in regions in the upstream intron (orange), exon body (purple), and
downstream intron (green) regions. B) Z-score of transformed TPM expression
male and female hSSCs (Fig. 5B).
values of candidate RBPs across the osteogenesis time course.
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Osteosarcoma vs. hSSCs

B)

Aged vs. young mouse SSCs
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Objectives

hSSC

In the present study, we aimed to characterize the relationship between AS and maintenance of
hSSCs, the skeletal niche, and osteosarcoma by identifying RNA-binding proteins (RBPs) involved
in cell maintenance and differentiation. We evaluate the effect of inhibiting these proteins on cell
viability and differentiation potential.

Methods

SF3b1

SF3b1

Cells are filtered and stained for surface markers
(PDPN+; CD164+; CD73+; Lin-; CD146-) and
sorted by FACS. hSSCs are lysed and processed for
RNA microarray analysis or plated for in-vitro
assays. Osteosarcoma cells U2OS and SAOS2 were
obtained from ATCC.
Large-scale RNA-seq data is processed using replicate Multivariate Analysis of Transcript Splicing
(rMATS) statistical model and its latest software
implementation rMATS-turbo to discover and
quantify alternative splicing.5,6 We developed a
computational approach to prioritize RBPs that
might orchestrate AS using time series data over a
12-day time-course of induced osteogenesis cell
culture (Fig 2B).

Figure 4: Gene expression commons microarray data from human and mouse SSCs and osteosarcoma cells. A) Comparison of SF3B6 and SF3B1 expression between 17 week old
hSSCs and osteosarcoma cell lines U2OS and SAOS2 shows elevated expression of these RBPs in osteosarcoma but lower in basal hSSCs. B) Age comparison of SF3B6 and SF3B1
expression between mouse SSCs aged P3, 8 weeks, and 2 years apart shows low expression at P3, increased expression at 8 weeks, then tapered expression at 2 years.
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Inhibition of AS may also be a potential treatment of osteosarcoma as demonstrated by chondrogenic differentiation assay (Fig. 6). Both U2OS and SAOS2 cell lines showed inhibited extracellular matrix formation and diminished
cell viability using small-molecule inhibition of AS. These results indicate the potential therapeutic targets for treatment of intractable bone cancers such as osteosarcoma.
The importance of AS in hSSCs is made clear by our study, but more work must be done to further reveal how the
transcriptional landscape of hSSCs changes during various cell stages. Critically, age differences in the expression
of RBPs are observed and may play a larger role in the features of skeletal aging, such as skewed lineage differentiation and limits to hSSC proliferation. Significant sex differences were not observed during our studies, but more
patient samples must be analyzed to determine whether sexual dimorphisms of the hSSC transcriptional landscape
occur.
We aim to further investigate the transcriptional targets of RBPs involved in hSSC differentiation, and to determine whether overexpression of these RBPs may instigate greater hSSC differentiation/proliferation.

RNA Microarray Analysis

Bones are provided by
our partners in Stanford department of
Surgery. hSSCs are exTissue
Antibody
Acute
Fx
Differentiation Assays
tracted from human
FACS
Digest
Staining
ORIF
bone and acute fracFigure 2: Steps in identifying RBPs and their functional impact in cells. A) Skeletal
ture-driven callus for- stem cells extracted from patient fractures are processed and sorted for RNA microaranalysis and differentiation. B) Computational pipeline for analyzing RNA microarmation and mechani- ray
ray data to discover RBPs and functional motifs.
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cally digested (Fig 2A).
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Future Directions
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A)

Osteosarcoma Cells with splicing inhibitors

We show osteogenic-related RBP expression increasing during osteoFigure 6: Chondrogenic assay of osteosarcoma cells with and without splicing inhibitors. Osteosarcoma cells U2OS and SAOS2
genesis, and knockdown of these exhibit increased formation of extracellular matrix (left, darker blue) with chondrogenic factors. Cell number and extracellular
formation is significantly inhibited in the presence of splicing inhibitors herboxidiene (1uM) and pladienolide B (1nM) for
RBPs
prevents
formation
of matrix
both chondrogenic factor exposure and normal culture conditions.
bone-forming lineages from SSCs.
These results indicate a potential target for bone deficiency disorders such as osteoporosis, osteoarthritis, and
age-related bone degeneration.

Evaluation of GEXC microarray data demonstrated differential expression of the RBPs SF3B6 and SF3B1 -- subunits of the human U2 spliceosome complex -- between B)
hSSCs and osteosarcoma cells (Fig. 4A). Similarly expression of these RBPs increases with age in mouse tissues
(Fig 4B).
Figure 1: Prospective isolation of human SSCs. SSCs can be extracted from human bone and sorted
using the above surface marker profile by fluorescence-assisted flow cytometry (FACS). These cells have
been shown to reconstitute the skeletal niche in mice and display differentiation potential towards bone,
cartilage, and stromal cells.
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Figure 5: Effect of AS inhibition on
hSSC differentiation and cell viability. A) Small molecules herboxidiene
and pladienolide B decrease cell viability by approximately 30% at highest concentration (10uM herboxidiene, 100nM pladienolide B) and
inhibit osteogenic differentiation in
29 and 55 year old males. Age-related differences in concentration-dependent inhibition is evident with
pladienolide B but not herboxidiene. B) Small molecule inhibition
limits the extend of extracellular
matrix formation characteristic of
chondrogenesis in male and female
SSCs.

We plan for in-vivo analysis of RBP expression using
rMATS through renal capsule transplantation, and will Figure 1: Plan for in-vivo engraftment of hSSCs onto the mouse kidney capsule for RNA-seq analyassess RNA expression at various time points (Fig.7). sis. hSSCs will be collected and analysed for RNA expression at day 0, 7, and week 8 post-engraftment timepoints for evaluation of RBP expression and motif enrichment.
Knockdown or overexpression of RBPs in engrafted SSCs
may provide insight into the potential to upregulate bone and cartilage formation in the mouse renal capsule
with translation applications to human autologous therapy.
We plan to investigate the potential therapeutic capacity of AS inhibition in osteosarcoma by local versus systemic
administration of small molecules in osteosarcoma-engrafted mice. Such results may offer an avenue for treatment
of intractable bone diseases and skeletal degeneration due to over-abundance of bone-resorbing cells.
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